Last reviewed 2026-04-20 · How we verify

Augmentin 250 (CLAVULANIC ACID)

Augmentin 250 (Clavulanate) is a beta-lactamase inhibitor developed by Dr. Reddy's Labs Inc. It is a small molecule modality that works by inhibiting bacterial beta-lactamase enzymes, thereby enhancing the effectiveness of penicillin-class antibiotics. Augmentin 250 is approved to treat various bacterial infections, including sinusitis, pneumonia, and urinary tract infections. It has been FDA-approved since 1984 and is currently owned by Dr. Reddy's Labs Inc. Key safety considerations include its short half-life of 0.9 hours and moderate bioavailability of 75%.

At a glance

Approved indications

• Acute bacterial sinusitis
• Bacterial infection due to Klebsiella pneumoniae
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Bacteroides Endometritis
• Bacteroides Peritonitis
• Citrobacter Urinary Tract Infection
• E. Coli Endometritis
• E. Coli Peritonitis
• Enterobacter Endometritis
• Escherichia coli urinary tract infection
• Haemophilus Influenzae Acute Otitis Media
• Haemophilus Parainfluenzae Pneumonia
• Haemophilus influenzae pneumonia
• Infection due to Escherichia coli
• Infection due to Staphylococcus aureus
• Infection of skin AND/OR subcutaneous tissue
• Infective otitis media
• Klebsiella Endometritis

Common side effects

No common side effects on file.

Key clinical trials

• APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
• Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
• Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients. (PHASE3)
• Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management
• Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
• Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
• Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
• A Platform Trial for Gram Negative Bloodstream Infections (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.